Biomarkers in traumatic brain injury

Current Neurology and Neuroscience Reports

Volumn 12, Issue 5, 2012, Pages 560-569

  Sharma, Richa ^a   Laskowitz, Daniel T ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Alpha II spectrin; Biomarkers; Clinical trials; Concussion; Diffuse axonal injury; End of life decisions; GFAP; Glasgow Coma Score; Hematoma; Inflammation; NSE; S100B; Traumatic brain injury

Indexed keywords

ALPHAA 2 SPECTRIN; ANTIOXIDANT; BIOLOGICAL MARKER; COMPLEMENT; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; ISOPROSTANE DERIVATIVE; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PENTRAXIN 3; PROTEIN S100B; RANTES; RESISTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTE; CELL ACTIVATION; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE SEVERITY; GLASGOW COMA SCALE; HUMAN; INFLAMMATION; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MORBIDITY; OXIDATIVE STRESS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; TRAUMATIC BRAIN INJURY;

ANIMALS; BIOLOGICAL MARKERS; BRAIN INJURIES; DECISION MAKING; GLASGOW COMA SCALE; HUMANS; PROGNOSIS;

EID: 84870562372     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0301-8     Document Type: Article

References (95)

1. Faul M, Xu L., Wald MM, Coronado VG, Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths.In: Centers for Disease Control and Prevention, Editor. Atlanta(GA): Centers for Disease Control and Prevention; 2010.
2. Neurological disorders: public health challenges. In: W.H. Organization, Editor. Geneva, Switzerland: WHO Press; 2006.
3. Thornhill S, et al. Disability in young people and adults one year after head injury: prospective cohort study. BMJ. 2000;320 (7250):1631-5. (Pubitemid 30364632)
4. Povlishock JT. The classification of traumatic brain injury (TBI) for targeted therapies. J Neurotrauma. 2008;25(7):717-8.
5. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728-41. (Pubitemid 351957931)
6. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2(7872):81-4.
7. Bruns Jr JJ, Jagoda AS. Mild traumatic brain injury. Mt Sinai J Med. 2009;76(2):129-37.
8. Affairs D.o.D.a.D.o.V. Traumatic brain Injury Task Force. 2008.
9. Saatman KE, Creed J, Raghupathi R. Calpain as a therapeutic target in traumatic brain injury. Neurotherapeutics. 2010;7(1):31-42.
10. McCullagh S, et al. Prediction of neuropsychiatric outcome following mild trauma brain injury: an examination of the Glasgow Coma Scale. Brain Inj. 2001;15(6):489-97. (Pubitemid 32586179)
11. Shenton ME, et al. A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury. Brain Imaging Behav. 2012.
12. Garnett MR, et al. Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury. Brain. 2000;123(Pt 10):2046-54.
13. Al-Samsam RH, Alessandri B, Bullock R. Extracellular N-acetylaspartate as a biochemical marker of the severity of neuronal damage following experimental acute traumatic brain injury. J Neurotrauma. 2000;17(1):31-9. (Pubitemid 30075614)
14. Babikian T, et al. Metabolic levels in the corpus callosum and their structural and behavioral correlates after moderate to severe pediatric TBI. J Neurotrauma. 2010;27(3):473-81.
15. Du Y, Li Y, Lan Q. 1 H-Magnetic resonance spectroscopy correlates with injury severity and can predict coma duration in patients following severe traumatic brain injury. Neurol India. 2011;59 (5):679-84.
16. Wendle J. Traumatic brain injury: Hidden Peril of U.S. Soldiers in Combat, in Time Magazine. March 19, 2012.
17. Healey C, et al. Improving the Glasgow Coma Scale score: motor score alone is a better predictor. J Trauma. 2003;54(4):671-8. discussion 678-80.
18. Daubin C, et al. Serum neuron-specific enolase as predictor of outcome in comatose cardiac-arrest survivors: a prospective cohort study. BMC Cardiovasc Disord. 2011;11:48.
19. Paraforou T, et al. Cerebral perfusion pressure, microdialysis biochemistry and clinical outcome in patients with traumatic brain injury. BMC Res Notes. 2011;4:540.
20. Frugier T, et al. In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J Neurotrauma. 2010;27(3):497-507.
21. Eddleston M, Mucke L. Molecular profile of reactive astrocytes- implications for their role in neurologic disease. Neuroscience. 1993;54(1):15-36. (Pubitemid 23147085)
22. Sawada M, et al. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989;491(2):394-7. (Pubitemid 19163393)
23. Rosenberg GA, et al. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res. 1995;703(1-2):151-5. (Pubitemid 3013581)
24. Ahn MJ, et al. The effects of traumatic brain injury on cerebral blood flow and brain tissue nitric oxide levels and cytokine expression. J Neurotrauma. 2004;21(10):1431-42.
25. Chen J, et al. Increased expression of TNF receptor-associated factor 6 after rat traumatic brain injury. Cell Mol Neurobiol. 2011;31(2):269-75.
26. Csuka E, et al. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol. 1999;101(2):211-21. (Pubitemid 29516464)
27. Goodman JC, et al. Elevation of tumor necrosis factor in head injury. J Neuroimmunol. 1990;30(2-3):213-7. (Pubitemid 20362754)
28. Ross SA, et al. The presence of tumour necrosis factor in CSF and plasma after severe head injury. Br J Neurosurg. 1994;8(4):419-25. (Pubitemid 24282529)
29. Gourin CG, Shackford SR. Production of tumor necrosis factoralpha and interleukin-1beta by human cerebral microvascular endothelium after percussive trauma. J Trauma. 1997;42 (6):1101-7. (Pubitemid 27287317)
30. Zhang X, et al. Caspase-8 expression and proteolysis in human brain after severe head injury. FASEB J. 2003;17(10):1367-9.
31. Helmy A, et al. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab. 2011;31(2):658-70.
32. Giulian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science. 1985;228(4698):497-9. (Pubitemid 15109103)
33. Carlson NG, et al. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol. 1999;163(7):3963-8. (Pubitemid 29450925)
34. Shiozaki T, et al. Cerebrospinal fluid concentrations of antiinflammatory mediators in early-phase severe traumatic brain injury. Shock. 2005;23(5):406-10. (Pubitemid 40571662)
35. Hutchinson PJ, et al. Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J Neurotrauma. 2007;24(10):1545-57. (Pubitemid 350035838)
36. Hillman J, et al. A microdialysis technique for routine measurement of macromolecules in the injured human brain. Neurosurgery. 2005;56(6):1264-8. discussion 1268-70. (Pubitemid 40770444)
37. Hillman J, et al. Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis. J Neurosurg. 2007;106(5):820-5. (Pubitemid 46698667)
38. Yoshioka N, et al. Small molecule inhibitor of type I transforming growth factor-beta receptor kinase ameliorates the inhibitory milieu in injured brain and promotes regeneration of nigrostriatal dopaminergic axons. J Neurosci Res. 2011;89 (3):381-93.
39. Huang RQ, et al. Preliminary study on the effect of trauma-induced secondary cellular hypoxia in brain injury. Neurosci Lett. 2010;473 (1):22-7.
40. Morganti-Kossmann MC, et al. TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood-brain barrier function. J Neurotrauma. 1999;16(7):617-28. (Pubitemid 29350520)
41. Polentarutti N, et al. Inducible expression of the long pentraxin PTX3 in the central nervous system. J Neuroimmunol. 2000;106 (1-2):87-94. (Pubitemid 30256081)
42. Ravizza T, et al. Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience. 2001;105 (1):43-53. (Pubitemid 32722092)
43. Gullo Jda S, et al. Hospital mortality of patients with severe traumatic brain injury is associated with serum PTX3 levels. Neurocrit Care. 2011;14(2):194-9.
44. Ahima RS, et al. Regulation of neuronal and glial proteins by leptin: implications for brain development. Endocrinology. 1999;140(6):2755-62. (Pubitemid 32245155)
45. Hayashi T, et al. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J Cereb Blood Flow Metab. 2003;23(2):166-80. (Pubitemid 36188455)
46. Dong XQ, et al. Resistin is associated with mortality in patients with traumatic brain injury. Crit Care. 2010;14(5):R190.
47. Kossmann T, et al. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab. 1997;17(3):280-9. (Pubitemid 27161371)
48. Semple BD, et al. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2-/- mice. J Cereb Blood Flow Metab. 2010;30(4):769-82.
49. Lumpkins K, et al. Plasma levels of the beta chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) correlate with severe brain injury. J Trauma. 2008;64(2):358-61. (Pubitemid 351640441)
50. Ghirnikar RS, et al. Chemokine expression in rat stab wound brain injury. J Neurosci Res. 1996;46(6):727-33. (Pubitemid 26425476)
51. Hughes PM, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia. 2002;37(4):314-27.
52. Rancan M, et al. The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury. J Cereb Blood Flow Metab. 2004;24(10):1110-8. (Pubitemid 39332150)
53. Bellander BM, et al. Complement activation in the human brain after traumatic head injury. J Neurotrauma. 2001;18(12):1295-311.
54. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol. 2009;68(3):217-26.
55. Bellander BM, et al. Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir (Wien). 2011;153(1):90-100.
56. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002;7:d1356-68.
57. Sorci G, et al. The many faces of S100B protein: when an extracellular factor inactivates its own receptor and activates another one. Ital J Anat Embryol. 2010;115(1-2):147-51.
58. Goncalves CA, Leite MC, Guerra MC. Adipocytes as an Important Source of Serum S100B and Possible Roles of This Protein in Adipose Tissue. Cardiovasc Psychiatry Neurol. 2010;2010:790431.
59. Pang X, et al. S100B protein as a possible participant in the brain metastasis of NSCLC. Med Oncol, 2012.
60. Egea-Guerrero JJ, et al. Accuracy of the S100beta protein as a marker of brain damage in traumatic brain injury. Brain Inj. 2012;26(1):76-82.
61. Rainey T, et al. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24 h) time-point. Resuscitation. 2009;80(3):341-5.
62. Kleinert K, et al. Is there a correlation between S100 beta and postconcussion symptoms after mild traumatic brain injury? Zentralbl Chir. 2010;135(3):277-8.
63. Unden J, et al. Serum S100B levels in patients with cerebral and extracerebral infectious disease. Scand J Infect Dis. 2004;36 (1):10-3. (Pubitemid 38219764)
64. Savola O, et al. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma. 2004;56 (6):1229-34. discussion 1234. (Pubitemid 38901833)
65. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol. 2005;17(2):167-71. (Pubitemid 40516286)
66. Buttner T, et al. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke. 1997;28 (10):1961-5. (Pubitemid 27459004)
67. Missler U, et al. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997;28(10):1956-60. (Pubitemid 27459003)
68. Elting JW, et al. Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci. 2000;181 (1-2):104-10.
69. Herrmann M, et al. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 2000;31 (11):2670-7.
70. Vos PE, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010;75 (20):1786-93.
71. Metting Z, et al. GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology. 2012;78(18):1428-33.
72. Foerch C, et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem. 2012;58(1):237-45.
73. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 1987;10:269-95. (Pubitemid 17022775)
74. Ross SA, et al. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg. 1996;10(5):471-6. (Pubitemid 26361431)
75. Meric E, et al. The prognostic value of neuron-specific enolase in head trauma patients. J Emerg Med. 2010;38(3):297-301.
76. Kies MW. Myelin basic protein. Scand J Immunol Suppl. 1982;9:125-46.
77. Liu MC, et al. Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J Neurochem. 2006;98(3):700-12.
78. Ottens AK, et al. Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. J Neurochem. 2008;104(5):1404-14. (Pubitemid 351293346)
79. Thomas DG, Palfreyman JW, Ratcliffe JG. Serum-myelin-basicprotein assay in diagnosis and prognosis of patients with head injury. Lancet. 1978;1(8056):113-5. (Pubitemid 8264234)
80. Yamazaki Y, et al. Diagnostic significance of serum neuronspecific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol. 1995;43(3):267-70. discussion 270-1.
81. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007;51(2-4):105-11. (Pubitemid 47179898)
82. Papa L, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med. 2010;38(1):138-44.
83. Brophy GM, et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma. 2011;28(6):861-70.
84. Hulsmeier J, et al. Distinct functions of alpha-Spectrin and beta-Spectrin during axonal pathfinding. Development. 2007;134 (4):713-22. (Pubitemid 46437913)
85. Pineda JA, et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 2007;24(2):354-66. (Pubitemid 46492156)
86. Cardali S, Maugeri R. Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci. 2006;50(2):25-31. (Pubitemid 44504149)
87. Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery. 1990;27 (1):1-11. (Pubitemid 20226076)
88. Zhang QG, et al. Critical role of NADPH oxidase in neuronal oxidative damage and microglia activation following traumatic brain injury. PLoS One. 2012;7(4):e34504.
89. Kochanek PM, et al. Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: Lessons learned from the bedside. Pediatr Crit Care Med. 2000;1(1):4-19.
90. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol. 1996;271(3 Pt 2):H1262-6.
91. Varma S, et al. F2-isoprostane and neuron-specific enolase in cerebrospinal fluid after severe traumatic brain injury in infants and children. J Neurotrauma. 2003;20(8):781-6. (Pubitemid 36993451)
92. Musiek ES, et al. Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799 (1):95-102. (Pubitemid 37500867)
93. Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma. 2000;17(5):367-88. (Pubitemid 30327300)
94. Bayir H, et al. Marked gender effect on lipid peroxidation after severe traumatic brain injury in adult patients. J Neurotrauma. 2004;21(1):1-8. (Pubitemid 38141797)
95. Bayir H, et al. Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr Res. 2002;51(5):571-8. (Pubitemid 34453572)